UnitedHealth Group Inc (NYSE:UNH) Director Gail R. Wilensky sold 2,930 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $253.39, for a total transaction of $742,432.70. Following the transaction, the director now owns 64,726 shares in the company, valued at approximately $16,400,921.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of UnitedHealth Group stock opened at $248.78 on Monday. UnitedHealth Group Inc has a twelve month low of $221.69 and a twelve month high of $287.94. The stock has a market capitalization of $238.71 billion, a P/E ratio of 19.32, a P/E/G ratio of 1.27 and a beta of 0.79. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.73 and a current ratio of 0.73.
UnitedHealth Group (NYSE:UNH) last released its earnings results on Tuesday, January 15th. The healthcare conglomerate reported $3.28 earnings per share for the quarter, beating the consensus estimate of $3.20 by $0.08. The business had revenue of $58.42 billion for the quarter, compared to the consensus estimate of $58.01 billion. UnitedHealth Group had a return on equity of 24.38% and a net margin of 5.30%. The business’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.59 earnings per share. Sell-side analysts forecast that UnitedHealth Group Inc will post 14.62 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 19th. Stockholders of record on Monday, March 11th were given a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a dividend yield of 1.45%. The ex-dividend date was Friday, March 8th. UnitedHealth Group’s dividend payout ratio (DPR) is 27.95%.
Several large investors have recently bought and sold shares of the company. Foyston Gordon & Payne Inc grew its stake in shares of UnitedHealth Group by 7.9% during the 3rd quarter. Foyston Gordon & Payne Inc now owns 80,948 shares of the healthcare conglomerate’s stock worth $21,535,000 after acquiring an additional 5,926 shares during the period. WINTON GROUP Ltd boosted its position in UnitedHealth Group by 15.7% during the third quarter. WINTON GROUP Ltd now owns 111,665 shares of the healthcare conglomerate’s stock worth $29,707,000 after purchasing an additional 15,181 shares during the period. Ballast Inc. boosted its position in UnitedHealth Group by 4.2% during the third quarter. Ballast Inc. now owns 12,583 shares of the healthcare conglomerate’s stock worth $3,348,000 after purchasing an additional 503 shares during the period. Gulf International Bank UK Ltd boosted its position in UnitedHealth Group by 4.3% during the third quarter. Gulf International Bank UK Ltd now owns 324,727 shares of the healthcare conglomerate’s stock worth $86,390,000 after purchasing an additional 13,246 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its position in UnitedHealth Group by 1.5% during the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 1,002,399 shares of the healthcare conglomerate’s stock worth $266,678,000 after purchasing an additional 14,553 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts recently commented on the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $310.00 target price on shares of UnitedHealth Group in a report on Tuesday, January 15th. Credit Suisse Group reaffirmed a “buy” rating and issued a $310.00 price objective on shares of UnitedHealth Group in a report on Friday, February 8th. Argus boosted their target price on shares of UnitedHealth Group from $285.00 to $295.00 and gave the company a “buy” rating in a research report on Monday, December 17th. Zacks Investment Research raised UnitedHealth Group from a “hold” rating to a “buy” rating and set a $305.00 price target on the stock in a research report on Friday, December 14th. Finally, Cleveland Research reissued a “buy” rating on shares of UnitedHealth Group in a report on Friday, January 11th. Three equities research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. UnitedHealth Group currently has an average rating of “Buy” and a consensus price target of $297.80.
UnitedHealth Group Company Profile
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children’s Health Insurance Program, and health care programs; and health and dental benefits.
Further Reading: Depreciation
Receive News & Ratings for UnitedHealth Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for UnitedHealth Group and related companies with MarketBeat.com’s FREE daily email newsletter.